SPARCL1, Shp2, MSH2, E-cadherin, p53, ADCY-2 and MAPK are prognosis-related in colorectal cancer

World Journal of Gastroenterology

Volumn 17, Issue 15, 2011, Pages 2028-2036

  Yu, Shu Jing ^a   Yu, Jie Kai ^a   Ge, Wei Ting ^a   Hu, Han Guang ^a   Yuan, Ying ^a   Zheng, Shu ^a  

^a THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Bioinformatics; Colorectal cancer; P53; Prognosis; Sparcl1

Indexed keywords

APC PROTEIN; ENDOTHELIN B RECEPTOR; GELATINASE B; HEAT SHOCK PROTEIN 27; MITOGEN ACTIVATED PROTEIN KINASE; NEUROLIGIN 1; PROTEIN ADCY 2; PROTEIN MSH2; PROTEIN P21RAS; PROTEIN P53; PROTEIN SPARCL1; PROTEIN TYROSINE PHOSPHATASE SHP 2; RHO FACTOR; TUMOR MARKER; UNCLASSIFIED DRUG; UVOMORULIN;

ADULT; ARTICLE; BIOINFORMATICS; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROTEIN EXPRESSION; SUPPORT VECTOR MACHINE;

EID: 79955941397     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v17.i15.2028     Document Type: Article

References (47)

1. Espey DK, Wu XC, Swan J, Wiggins C, Jim MA, Ward E, Wingo PA, Howe HL, Ries LA, Miller BA, Jemal A, Ahmed F, Cobb N, Kaur JS, Edwards BK. Annual report to the nation on the status of cancer, 1975-2004, featuring cancer in American Indians and Alaska Natives. Cancer 2007; 110: 2119-2152
2. Jemal A, Clegg LX, Ward E, Ries LA, Wu X, Jamison PM, Wingo PA, Howe HL, Anderson RN, Edwards BK. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer 2004; 101: 3-27
3. Parsons DW, Wang TL, Samuels Y, Bardelli A, Cummins JM, DeLong L, Silliman N, Ptak J, Szabo S, Willson JK, Mar-kowitz S, Kinzler KW, Vogelstein B, Lengauer C, Velculescu VE. Colorectal cancer: mutations in a signalling pathway. Nature 2005; 436: 792
4. Wood LD, Parsons DW, Jones S, Lin J, Sjöblom T, Leary RJ, Shen D, Boca SM, Barber T, Ptak J, Silliman N, Szabo S, Dezso Z, Ustyanksky V, Nikolskaya T, Nikolsky Y, Karchin R, Wilson PA, Kaminker JS, Zhang Z, Croshaw R, Willis J, Dawson D, Shipitsin M, Willson JK, Sukumar S, Polyak K, Park BH, Pethiyagoda CL, Pant PV, Ballinger DG, Sparks AB, Hartigan J, Smith DR, Suh E, Papadopoulos N, Buck-haults P, Markowitz SD, Parmigiani G, Kinzler KW, Vel-culescu VE, Vogelstein B. The genomic landscapes of human breast and colorectal cancers. Science 2007; 318: 1108-1113
5. Vapnik VN. Statistical Learning Theory. New York: Wiley, 1998
6. Liu Y. Active learning with support vector machine applied to gene expression data for cancer classifcation. J Chem Inf Comput Sci 2004; 44: 1936-1941
7. Meng PQ, Hou G, Zhou GY, Peng JP, Dong Q, Zheng S. Application of new tissue microarrayer-ZM-1 without recipient paraffn block. J Zhejiang Univ Sci B 2005; 6: 853-858
8. Elkhuizen PH, Hermans J, Leer JW, van de Vijver MJ. Isolated late local recurrences with high mitotic count and early local recurrences following breast-conserving therapy are associated with increased risk on distant metastasis. Int J Radiat Oncol Biol Phys 2001; 50: 387-396
9. O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 2004; 96: 1420-1425
10. Chan RJ, Feng GS. PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase. Blood 2007; 109: 862-867
11. Kathpalia VP, Mussak EN, Chow SS, Lam PH, Skelley N, Time M, Markelewicz RJ Jr, Kanduc D, Lomas L, Xiang Z, Sinha AA. Genome-wide transcriptional profiling in human squamous cell carcinoma of the skin identifes unique tumor-associated signatures. J Dermatol 2006; 33: 309-318
12. Tao XH, Shen JG, Pan WL, Dong YE, Meng Q, Honn KV, Jin R. Significance of SHP-1 and SHP-2 expression in human papillomavirus infected Condyloma acuminatum and cervical cancer. Pathol Oncol Res 2008; 14: 365-371
13. Zhou X, Coad J, Ducatman B, Agazie YM. SHP2 is up-regulated in breast cancer cells and in infiltrating ductal carcinoma of the breast, implying its involvement in breast oncogenesis. Histopathology 2008; 53: 389-402
14. Losi L, Ponti G, Gregorio CD, Marino M, Rossi G, Pedroni M, Benatti P, Roncucci L, de Leon MP. Prognostic significance of histological features and biological parameters in stage I (pT1 and pT2) colorectal adenocarcinoma. Pathol Res Pract 2006; 202: 663-670
15. Lanza G, Gafà R, Santini A, Maestri I, Guerzoni L, Cavazzini L. Immunohistochemical test for MLH1 and MSH2 expression predicts clinical outcome in stage II and III colorectal cancer patients. J Clin Oncol 2006; 24: 2359-2367
16. Jensen LH, Danenberg KD, Danenberg PV, Jakobsen A. Predictive value of MSH2 gene expression in colorectal cancer treated with capecitabine. Clin Colorectal Cancer 2007; 6: 433-435
17. Bendardaf R, Lamlum H, Ristamäki R, Syrjänen K, Pyrhönen S. Oncoprotein Bcl-2 and microsatellite instability are associated with disease-free survival and treatment response in colorectal cancer. Oncol Rep 2008; 20: 999-1004
18. Platanias LC. Map kinase signaling pathways and hematologic malignancies. Blood 2003; 101: 4667-4679
19. Ajenjo N, Cañón E, Sánchez-Pérez I, Matallanas D, León J, Perona R, Crespo P. Subcellular localization determines the protective effects of activated ERK2 against distinct apop-togenic stimuli in myeloid leukemia cells. J Biol Chem 2004; 279: 32813-32823
20. Beavon IR. The E-cadherincatenin complex in tumour metastasis: structure, function and regulation. Eur J Cancer 2000; 36: 1607-1620
21. Delektorskaya VV, Perevoshchikov AG, Golovkov DA, Kushlinskii NE. Expression of E-cadherin, beta-catenin, and CD-44v6 cell adhesion molecules in primary tumors and metastases of colorectal adenocarcinoma. Bull Exp Biol Med 2005; 139: 706-710
22. Zia F, Fagarasan M, Bitar K, Coy DH, Pisegna JR, Wank SA, Moody TW. Pituitary adenylate cyclase activating peptide receptors regulate the growth of non-small cell lung cancer cells. Cancer Res 1995; 55: 4886-4891
23. Buscail L, Cambillau C, Seva C, Scemama JL, De Neef P, Robberecht P, Christophe J, Susini C, Vaysse N. Stimulation of rat pancreatic tumoral AR4-2J cell proliferation by pituitary adenylate cyclase-activating peptide. Gastroenterology 1992; 103: 1002-1008
24. Steele RJ, Lane DP. P53 in cancer: a paradigm for modern management of cancer. Surgeon 2005; 3: 197-205
25. Oka M, Kounoura K, Narasaki F, Sakamoto A, Fukuda M, Matsuo I, Ikeda K, Tsurutani J, Ikuno N, Omagari K, Mizuta Y, Soda H, Gudas JM, Kohno S. P-glycoprotein is positively correlated with p53 protein accumulation in human colorec-tal cancers. Jpn J Cancer Res 1997; 88: 738-742
26. Swisher SG, Roth JA, Komaki R, Gu J, Lee JJ, Hicks M, Ro JY, Hong WK, Merritt JA, Ahrar K, Atkinson NE, Correa AM, Dolormente M, Dreiling L, El-Naggar AK, Fossella F, Francisco R, Glisson B, Grammer S, Herbst R, Huaringa A, Kemp B, Khuri FR, Kurie JM, Liao Z, McDonnell TJ, Morice R, Morello F, Munden R, Papadimitrakopoulou V, Pisters KM, Putnam JB Jr, Sarabia AJ, Shelton T, Stevens C, Shin DM, Smythe WR, Vaporciyan AA, Walsh GL, Yin M. Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res 2003; 9: 93-101
27. Fujimoto K, Yamada Y, Okajima E, Kakizoe T, Sasaki H, Sug-imura T, Terada M. Frequent association of p53 gene mutation in invasive bladder cancer. Cancer Res 1992; 52: 1393-1398
28. Esrig D, Elmajian D, Groshen S, Freeman JA, Stein JP, Chen SC, Nichols PW, Skinner DG, Jones PA, Cote RJ. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 1994; 331: 1259-1264
29. Sarkis AS, Bajorin DF, Reuter VE, Herr HW, Netto G, Zhang ZF, Schultz PK, Cordon-Cardo C, Scher HI. Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. J Clin Oncol 1995; 13: 1384-1390
30. Noske A, Lipka S, Budczies J, Müller K, Loddenkemper C, Buhr HJ, Kruschewski M. Combination of p53 expression and p21 loss has an independent prognostic impact on sporadic colorectal cancer. Oncol Rep 2009; 22: 3-9
31. Adhikari AS, Iwakuma T. Mutant p53 gain of oncogenic function: in vivo evidence, mechanism of action and its clinical implications. Fukuoka Igaku Zasshi 2009; 100: 217-228
32. Al-Joudi FS, Iskandar ZA, Rusli J. The expression of p53 in invasive ductal carcinoma of the breast: a study in the North-East States of Malaysia. Med J Malaysia 2008; 63: 96-99
33. Zhu ZZ, Liu B, Wang AZ, Jia HR, Jin XX, He XL, Hou LF, Zhu GS. Association of p53 codon 72 polymorphism with liver metastases of colorectal cancers positive for p53 over-expression. J Zhejiang Univ Sci B 2008; 9: 847-852
34. Girard JP, Springer TA. Cloning from purified high endothelial venule cells of hevin, a close relative of the antiadhesive extracellular matrix protein SPARC. Immunity 1995; 2: 113-123
35. Nelson PS, Plymate SR, Wang K, True LD, Ware JL, Gan L, Liu AY, Hood L. Hevin, an antiadhesive extracellular matrix protein, is down-regulated in metastatic prostate adenocar-cinoma. Cancer Res 1998; 58: 232-236
36. Schraml P, Shipman R, Colombi M, Ludwig CU. Identification of genes differentially expressed in normal lung and non-small cell lung carcinoma tissue. Cancer Res 1994; 54: 5236-5240
37. Esposito I, Kayed H, Keleg S, Giese T, Sage EH, Schirm-acher P, Friess H, Kleeff J. Tumor-suppressor function of SPARC-like protein 1/Hevin in pancreatic cancer. Neoplasia 2007; 9: 8-17
38. Bendik I, Schraml P, Ludwig CU. Characterization of MAST9/Hevin, a SPARC-like protein, that is down-regulated in non-small cell lung cancer. Cancer Res 1998; 58: 626-629
39. Lau CP, Poon RT, Cheung ST, Yu WC, Fan ST. SPARC and Hevin expression correlate with tumour angiogenesis in hepatocellular carcinoma. J Pathol 2006; 210: 459-468
40. Popat S, Houlston RS. A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis. Eur J Cancer 2005; 41: 2060-2070
41. Westra JL, Schaapveld M, Hollema H, de Boer JP, Kraak MM, de Jong D, Ter Elst A, Mulder NH, Buys CH, Hofstra RM, Plukker JT. Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients. J Clin Oncol 2005; 23: 5635-5643
42. Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, Dietrich D, Biesmans B, Bodoky G, Barone C, Aranda E, Nordlinger B, Cisar L, Labianca R, Cunningham D, Van Cutsem E, Bosman F. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the transla- tional study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010; 28: 466-474
43. French AJ, Sargent DJ, Burgart LJ, Foster NR, Kabat BF, Goldberg R, Shepherd L, Windschitl HE, Thibodeau SN. Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer. Clin Cancer Res 2008; 14: 3408-3415
44. Lanza G, Matteuzzi M, Gafá R, Orvieto E, Maestri I, Santini A, del Senno L. Chromosome 18q allelic loss and prognosis in stage II and III colon cancer. Int J Cancer 1998; 79: 390-395
45. Halling KC, French AJ, McDonnell SK, Burgart LJ, Schaid DJ, Peterson BJ, Moon-Tasson L, Mahoney MR, Sargent DJ, O'Connell MJ, Witzig TE, Farr GH Jr, Goldberg RM, Thibodeau SN. Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers. J Natl Cancer Inst 1999; 91: 1295-1303
46. Popat S, Zhao D, Chen Z, Pan H, Shao Y, Chandler I, Houlston RS. Relationship between chromosome 18q status and colorectal cancer prognosis: a prospective, blinded analysis of 280 patients. Anticancer Res 2007; 27: 627-633
47. Meyerhardt JA, Fuchs CS. Prognostic significance and molecular associations of 18q loss of heterozygosity: a cohort study of microsatellite stable colorectal cancers. J Clin Oncol 2009; 27: 4591-4598